For the past two weeks I've been interfacing with the spouse of an ICU patient, both friends, at a major NYC hospital. Excellent reputation, quality care, etc etc. They kept telling the spouse that they never heard of Leronlimab, but Sarilumab was the same thing and better because it was already approved. The spouse asked just about every time (as the patient was showing no signs of improvement and eventually got a secondary infection from being on the Sarilumab and ventilator for so long) and was basically ignored until the trial was dropped.

Once that trial was no longer active, she sent a bunch of links on Leronlimab, it's MOA, safety profile, etc etc, along and her patient advocate was floored. They knew of Leronlimab from the HIV trials, saw the safety profile, grasped the MOA. Last I heard they're getting an EIND together and asking the trial team why they went for the Sarilumab trial when this was available.

I have a feeling I know the answer